A practical reference on GHRH receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
=== Triggers === Several environmental factors have been postulated to modify illness susceptibility or induce disease; the most persuasive of these is the role of female sex hormones, as evidenced by the disease's significant female-to-male ratio and other data. Furthermore, investigations indicate that Epstein–Barr virus, retroviruses, or other viruses may play a role in causing disease in some patients. Cytomegalovirus has also been proposed as capable of eliciting anti-RNP antibody responses in the absence of illness. Environmental exposure to vinyl chloride has been linked to the development of an MCTD-like condition.
thiol 1. Any of a class of organosulfur compounds consisting of a sulfur atom attached to a hydrogen atom and any other organic substituent, with the general formula R–SH. Thiols are the sulfur analogues of alcohols. Also thiol derivative and mercaptan. 2. The –SH functional group itself. Also sulfhydryl, sulfanyl, and mercapto.
As of January 2026, there were 575 federally recognized tribes. There are approximately 326 Indian reservations. The tribes hold a government-to-government relationship with the U.S. federal government in Washington and are legally defined as domestic dependent nations with inherent tribal sovereignty rights. In addition to the five major territories, the U.S. also asserts sovereignty over the United States Minor Outlying Islands in the Pacific Ocean and the Caribbean. The seven undisputed islands without permanent populations are Baker Island, Howland Island, Jarvis Island, Johnston Atoll, Kingman Reef, Midway Atoll, and Palmyra Atoll. U.S. sovereignty over the unpopulated Bajo Nuevo Bank, Navassa Island, Serranilla Bank, and Wake Island is disputed.
== Role in cell signaling == Protein quaternary structure also plays an important role in certain cell signaling pathways. The G protein-coupled receptor pathway involves a heterotrimeric protein known as a G protein. G proteins contain three distinct subunits known as the G-alpha, G-beta, and G-gamma subunits. When the G protein is activated, it binds to the G protein-coupled receptor protein and the cell signaling pathway is initiated. Another example is the receptor tyrosine kinase (RTK) pathway, which is initiated by the dimerization of two receptor tyrosine kinase monomers. When the dimer is formed, the two kinases can phosphorylate each other and initiate a cell signaling pathway.
Sources: en.wikipedia.org
== Research contributions == Esimone pioneered research in the use of recombinant viral vectors as surrogates for high-throughput antiviral screening studies, as well as on the use of indigenous medicinal plants as immunomodulators, vaccine adjuvants, and anti-infectives. The vector-based antiviral screening technique developed by Esimone between 2003 and 2005 in Germany significantly revolutionized high-throughput screening for anti-HIV compounds worldwide. In addition to this work, his research led to the discovery of new antimicrobial compounds—including antibacterial, antifungal, and antiviral agents—derived from endophytes, lichens, ferns, herbs, and spices. Esimone was instrumental in the isolation and characterization of resistance genes from clinical settings, abattoirs, and poultry, with a particular focus on extended-spectrum beta-lactamases (ESBLs) and metallo-beta-lactamases (MBLs) identified in the southeastern regions of Nigeria. His team became the first to demonstrate the presence of ESBL-producing bacteria harboring the CTXM-15 gene, which confers resistance to third-generation cephalosporins in Nigeria. Additionally, they were the first to identify MBL-producing bacteria containing the blaIMP-1 and blaVIM-1 genes within poultry and abattoirs in southeastern Nigeria. They also reported the increasing frequency of MBL-producing Klebsiella, Pseudomonas, and Escherichia species in the country.
One way to bypass these issues is the use of droplets to compartmentalize separation bands, which combats diffusion and the loss of separated analytes. In early attempts to integrate chromatography with droplet microfluidics, the lower flow rates and pressures required for 2-D capillary LC provided less of an obstacle to overcome in combining these technologies and made it possible to couple multiple 2-D separation techniques into one device (i.e. HPLC x LC, LC x LC, and HPLC x HPLC). HPLC autosamplers feeding into microfluidic devices have taken advantage of the dispersion occurring between separation and droplet formation to feed gradient pulses of analytes into microfluidic devices where the production of thousands of pico-liter droplets captures unique analyte concentrations. Similar approaches have used the withdrawal capabilities of a syringe pump to align the relatively high flow rates necessary for HPLC with the lower flow rates of the continuous medium common in microfluidic devices. The development of nano-LC, or nano-UPLC, has provided another opportunity for coupling with microfluidic devices such that large droplet libraries can be formed with multiple dimensions of information being stored in each droplet. Instead of identifying peaks and storing them as a single sample, as seen in standard LC, these droplet libraries allow for the specific concentration of the analyte to be retained along with its identity.
=== Metrology for VOC measurements === To achieve comparability of VOC measurements, reference standards traceable to SI units are required. For a number of VOCs gaseous reference standards are available from specialty gas suppliers or national metrology institutes, either in the form of cylinders or dynamic generation methods. However, for many VOCs, such as oxygenated VOCs, monoterpenes, or formaldehyde, no standards are available at the appropriate amount of fraction due to the chemical reactivity or adsorption of these molecules. Currently, several national metrology institutes are working on the lacking standard gas mixtures at trace level concentration, minimising adsorption processes, and improving the zero gas. The final scopes are for the traceability and the long-term stability of the standard gases to be in accordance with the data quality objectives (DQO, maximum uncertainty of 20% in this case) required by the WMO/GAW program.
Sources: en.wikipedia.org
== Research and career == In 1975, Theo Wallimann completed his Ph.D. Dissertation on “M-line-bound Creatine Kinase and Myofibrillar Structure” in the laboratory of Prof. Hans M. Eppenberger at the Institute of Cell Biology at ETH Zurich with distinction and received the ETH prize and medal. From 1975 - 1981, Wallimann worked as a post-doctoral research associate with Andrew G. Szent-Györgyi , at the Biology Department of Brandeis University on the subject of "Myosin-linked calcium regulation of muscle contraction". After rejoining the Biology Dept of the ETH-Zurich in 1981, Wallimann became a Lecturer in 1984 with his Habilitation on: "Localization and function of M-line-bound creatine kinase: M-band model and Phospho-Creatine Shuttle"). In 1994, Wallimann was awarded the title of Professor and in the next two years he became Head and Deputy Head of the Institute of Cell Biology. Wallimann resigned from his post in June 2008 and is now Emeritus and member of the ETH Alumni organisation. In 2005, Wallimann was awarded with the Alfred-Vogt-Prize in 2005 and in 2023, 2024 and 2025 he received the Research.com Recognition Leader Award for Biology and Biochemistry in Switzerland. In 2025, Theo Wallimann has been honored by the International Society of Sports Nutrition with a “Life-time Achievement Award” for his research on the «Creatine Kinase System and Creatine», at the Internatl. Congress on «Creatine for Health», held during March 12th-16th 2025 in Munich, Germany: https://creatineforhealth.com/creatine-conference-2025/
== Biocultural bioarchaeology == The study of human remains can illuminate the relationship between physical bodies and socio-cultural conditions and practices, via a biocultural bioarchaeology model. Bioarchaeology is typically regarded as a positivist, science-based discipline, while the social sciences are regarded as constructivist. Bioarchaeology has been criticized for having little to no concern for culture or history. One scholar argued that scientific/forensic scholarship ignores cultural/historic factors. He proposed that a biocultural version of bioarchaeology offered a more meaningful, nuanced, and relevant picture, especially for descent populations. Biocultural bioarchaeology combines standard forensic techniques with investigations of demography and epidemiology in order to assess socioeconomic conditions experienced by human communities. For example, incorporation of analysis of grave goods can further the understanding of daily activities. Some bioarchaeologists view the discipline as a crucial interface between the science and the humanities; as the human body is made and re-made by both biological and cultural factors. Another type of bioarchaeology focuses on quality of life, lifestyle, behavior, biological relatedness, and population history. It does not closely link skeletal remains to their archaeological context, and may best be viewed as a "skeletal biology of the past". Inequalities exist in all human societies.
The formation of such a heterochromatin region, though not its maintenance, is Dicer-dependent, presumably because Dicer is required to generate the initial complement of siRNAs that target subsequent transcripts. Heterochromatin maintenance has been suggested to function as a self-reinforcing feedback loop, as new siRNAs are formed from the occasional nascent transcripts by RdRP for incorporation into local RITS complexes. The relevance of observations from fission yeast mating-type regions and centromeres to mammals is not clear, as heterochromatin maintenance in mammalian cells may be independent of the components of the RNAi pathway.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.